Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma
NCT00501826Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2007
- Primary completion
- Oct 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nelarabine, pegaspargase, venetoclax in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2007; status: recruiting.
02
Drugs
nelarabinepegaspargasevenetoclax
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT00501826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501826.